pabrinex n/a solution for inj/inf
archimedes pharma uk limited - thiamine hydrochloride, riboflavin, pyridoxine hydrochloride, nicotinamide, ascorbic acid, glucose (as monohydrate) - solution for inj/inf - n/a - vitamin b-complex with vitamin c
chlorphenamine 10 mg/ml solution for injection
archimedes pharma uk limited - chlorphenamine maleate - solution for injection - 10 mg/ml - substituted alkylamines
thiopental sodium 500 milligram pdr for soln for injection
archimedes pharma uk limited - thiopental sodium - pdr for soln for injection - 500 milligram - barbiturates, plain
apomorphine hydrochloride
archimedes pharma uk limited - apomorphine hydrochloride - solution for inj/inf - 10 mg/ml
apomorphine hydrochloride 10 mg/ml solution for inj/inf
archimedes pharma uk limited - apomorphine hydrochloride - solution for inj/inf - 10 mg/ml
pro-banthine coated tablets 15 milligram
archimedes pharma uk limited - propantheline bromide - coated tablets - 15 milligram
pro-banthine 15 milligram coated tablets
archimedes pharma uk limited - propantheline bromide - coated tablets - 15 milligram
opilon tablets 40 milligram
archimedes pharma uk limited - moxisylyte hydrochloride - tablets - 40 milligram
opilon 40 milligram tablets
archimedes pharma uk limited - moxisylyte hydrochloride - tablets - 40 milligram
lazanda- fentanyl citrate spray
archimedes pharma us inc. - fentanyl citrate (unii: mun5lyg46h) (fentanyl - unii:uf599785jz) - fentanyl 100 ug - lazanda (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. patients must remain on around-the-clock opioids when taking lazanda. lazanda is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could occur in patients not taking chronic opioids. for this reason, lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, or dental pain. [4] lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and